Ocera Therapeutics, Inc. OCRX
No live quote for OCRX yet.
Analyst view
Consensus: buy
Buy
Price target (mean) 6.38
- Target (low)
- 1.75
- Target (mean)
- 6.38
- Target (high)
- 11.00
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 3
- 2 months ago 3
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.22 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.28 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2017 | H.C. Wainwright | Downgrade | Buy | Neutral |
| Jan 30, 2017 | JMP Securities | Downgrade | — | Market Perform |
| Dec 27, 2016 | H.C. Wainwright | Initiated | — | Buy |
| Nov 3, 2016 | Aegis Capital | Initiated | — | Buy |
| Feb 22, 2016 | Brean Capital | Initiated | — | Buy |
| Mar 11, 2015 | Stifel Nicolaus | Maintained | — | Buy |
| Aug 11, 2014 | Stifel Nicolaus | Maintained | — | Buy |
| Jun 10, 2014 | JMP Securities | Initiated | — | Market Outperform |
| Jan 5, 2014 | BMO Capital | Upgrade | — | Outperform |
| Dec 29, 2013 | Stifel Nicolaus | Initiated | — | Buy |